In 2009, total sales of smoking-cessation products surpassed $1.6bn (Rx products).
The report predicts that the launch of new smoking-cessation aids early this decade will answer some unmet needs currently limiting that pharma market segment. Besides extensive coverage of currently-marketed drugs, this report examines the most exciting products currently in development. The report also includes external opinions on the sector, gained thorough original unique surveys. The report analyses current leading markets in North America, Europe and Asia in detail. A major contribution to the market during the next 15 years will come from emerging economies, led by India and China. Almost half of the world’s smokers live in those countries, with almost a third in China alone, reports suggest. At present, those national markets yield relatively low smoking-cessation revenues. However, the report predicts that the emerging economies have a large potential for sales growth of smoking-cessation products. This report reveals how their sales revenues and market shares will expand during the forecast period.
Update: An Anonymous comment brings this to our attention - reinforcing my point that the "anti-smoking" campaigns are, in truth, mostly ramps for drugs companies:
The heads of Pharmacia & Upjohn and Glaxo Wellcome both expressed their appreciation for the joint partnership.
"I'm delighted that Pharmacia & Upjohn is a leader in this ground-breaking action partnership with WHO to combat tobacco dependence," Fred Hassan, Pharmacia & Upjohn's President and Chief Executive Officer says. "Public health threats of this magnitude and urgency require the collaborative efforts of both the public and private sectors if we are to significantly reduce harm in a timely fashion. We hope that this initiative will serve as a model for other such partnerships."
"This partnership with the World Health Organization offers great promise in the effort to reduce tobacco dependence and thus reduce the significant health costs and burden of tobacco-related illnesses and deaths," said Sir Richard Sykes, Chairman, Glaxo Wellcome plc. "As a company, our commitment is to fighting disease. Tobacco dependence is in every sense of the word a disease with major but reversible health implications. Together, we can defeat this disease."